Find where to buy products from suppliers in the USA, including: distributors, industrial manufacturers in America, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the American suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the UK.
| Product | Description | |
|---|---|---|
| B-Raf inhibitor | aA B-Raf inhibitor, pyrazine and pyrrolo[2,3-b]pyridine derivatives, useful in the treatment of cancer and proliferative diseases. Synonyms: Benzamide, N-[4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-4-methyl-3-[(6-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy]-. Grade: >98%. CAS No. 1315330-11-0. Molecular formula: C29H31F3N6O2. Mole weight: 552.59. |  |
| B-Raf inhibitor 1 | B-Raf inhibitor 1 is a potent and selective B-Raf inhibitor with cell IC50s of 0.31 μM and 2 nM for A375 proliferation and A375 p-ERK respectively. Synonyms: B-Raf Inhibitor 1; B-Raf-Inhibitor 1; B-Raf-Inhibitor-1; MDK0403; MDK-0403; MDK 0403. Grade: >98%. CAS No. 1093100-40-3. Molecular formula: C26H19ClN8. Mole weight: 478.94. | |
| B-Raf inhibitor 1 dihydrochloride | B-Raf inhibitor 1 is an inhibitor of B-Raf kinase with IC50 values of 0.31μM and 0.72μM for cell proliferation, respectively in A375 and HCT116. B-Raf is important in signal transduction and some mutant B-Raf occurs in cancer cells. The most common mutation of these is V600E, which makes B-Raf kinase constitutively active. B-Raf inhibitor 1 belongs to the type IIA inhibitors and binds to the DFG-out ATP-binding site of B-Raf. The selectivity of B-Raf inhibitor 1 is less than of other type inhibitors. Besides mutant B-Raf, it can also inhibit wild type B-Raf and other tyrosine kinase. In cells with wild type B-Raf, B-Raf inhibitor 1 can activate the RAF-MEK-ERK signaling pathway via Raf dimerization. The preclinical toxicity test shows B-Raf inhibitor 1 can induce hyperplasia in a mouse model. Synonyms: 1,5-Isoquinolinediamine, N1-(4-chlorophenyl)-6-methyl-N5-[3-(9H-purin-6-yl)-2-pyridinyl]-, hydrochloride (1:2). Grade: >98%. CAS No. 1191385-19-9. Molecular formula: C26H21Cl3N8. Mole weight: 551.86. | |
| 1,3-Bis(6-chloro-2',3'-difluoro-[1,1'-biphenyl]-3-yl)urea | 1,3-Bis(6-chloro-2',3'-difluoro-[1,1'-biphenyl]-3-yl)urea is one of Sorafenib impurities. Sorafenib is a polykinase inhibitor of Raf-1, B-Raf and VEGFR-2 and is an anti-tumor drug. Molecular formula: C25H14Cl2F4N2O. Mole weight: 505.29. | |
| 2,2,3,3-Tetrafluoro-2,3-dihydro-1,4-benzodioxin-5-amine | 2,2,3,3-Tetrafluoro-2,3-dihydro-1,4-benzodioxin-5-amine can be used to synthesize derivatives of 2- (3, 4, 5-trimethoxyphenylamino) -6- (3-acetamidophenyl) pyrazine as B-RAF inhibitors. Group: Biochemicals. Grades: Highly Purified. CAS No. 119895-70-4. Pack Sizes: 5mg, 50mg. Molecular Formula: C8H5F4NO2, Molecular Weight: 223.12. US Biological Life Sciences. |  Worldwide |
| 2,4,5-Trifluoroacetophenone | 2,4,5-Trifluoroacetophenone is a reagent in the preparation of indazolyl pyrazolopyrimidines as type I B-Raf inhibitors with antitumor activity. Group: Biochemicals. Grades: Highly Purified. CAS No. 129322-83-4. Pack Sizes: 250mg, 1g. Molecular Formula: C8H5F3O, Molecular Weight: 174.12. US Biological Life Sciences. | Worldwide |
| 2, 6-Difluoro-N- (3-methoxy-1H-pyrazolo[3, 4-b]pyridin-5yl) -3- (propylsulfonamido) benzamide | 2, 6-Difluoro-N- (3-methoxy-1H-pyrazolo[3, 4-b]pyridin-5yl) -3- (propylsulfonamido) benzamide is a potent, selective, and orally bioavailable inhibitor of B-RafV600E. Group: Biochemicals. Grades: Highly Purified. CAS No. 1186607-05-5. Pack Sizes: 500ug, 5mg. Molecular Formula: C17H17F2N5O4S, Molecular Weight: 425.41. US Biological Life Sciences. | Worldwide |
| 2-Acetamido-3-bromo-5-nitropyridine | 2-Acetamido-3-bromo-5-nitropyridine is a general chemical reagent used in the synthesis of pharmaceutically active compounds and inhibitors. Used in the production of b-Raf inhibitors for the treatment of cancer. Group: Biochemicals. Grades: Highly Purified. CAS No. 1065074-93-2. Pack Sizes: 1g, 5g. Molecular Formula: C7H6BrN3O3, Molecular Weight: 260.04. US Biological Life Sciences. | Worldwide |
| 4-(4-Aminophenoxy)-2-pyridinecarboxamide | 4-(4-Aminophenoxy)-2-pyridinecarboxamide is one of Sorafenib intermediates. Sorafenib is a polykinase inhibitor of Raf-1, B-Raf and VEGFR-2 and is an anti-tumor drug. Synonyms: 4-(2-Carbamoyl-4-pyridyloxy)aniline; 4-(4-Aminophenoxy)picolinamide; 4-(4-amino-phenoxy)-pyridine-2-carboxylic acid amide; 2-Pyridinecarboxamide, 4-(4-aminophenoxy)-; Sorafenib tosylate Impurity 8; 4-(2-carbamoyl-pyridin-4-yloxy)aniline. Grade: 95%. CAS No. 284462-80-2. Molecular formula: C12H11N3O2. Mole weight: 229.23. | |
| 5-Methoxy-1H-pyrazol-3-amine | 5-Methoxy-1H-pyrazol-3-amine is used in the preparation of pyrazolopyridine inhibitors of B-RafV600E. Group: Biochemicals. Alternative Names: (5-Methoxy-1H-pyrazol-3-yl)amine. Grades: Highly Purified. CAS No. 41307-23-7. Pack Sizes: 25mg. US Biological Life Sciences. | Worldwide |
| AMG-628 | AMG-628 is a highly selective, ATP-competitive inhibitor of Raf kinases. It can inhibit activation of tyrosine protein kinases. AMG-628 can also inhibit growth, and induce cell cycle arrest and apoptosis in colon and melanoma cell lines with the B-RafV600E mutation. Synonyms: AMG-628; AMG 628; AMG628; UNII-28J966TN3X; CHEMBL226574; N-(4-((6-(4-(1-(4-fluorophenyl)ethyl)-1-piperazinyl)-4-pyrimidinyl)oxy)-2-benzothiazolyl)-Acetamide. Grade: 98%. CAS No. 862269-73-6. Molecular formula: C25H25FN6O2S. Mole weight: 492.57. | |
| AMG PERK 44 | AMG PERK 44 is an orally active and highly selective PERK inhibitor with an IC50 of 6 nM. AMG PERK 44 has 1000-fold and 160-fold selectivity over GCN2 (IC50=7300 nM) and B-Raf (IC50 >1000 nM), respectively. AMG PERK 44 induces autophagy[1][2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1883548-84-2. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-12661A. |  |
| AMG PERK 44 | AMG PERK 44 is a potent and selective PERK inhibitor with IC50 of 6 nM, which exhibits 160-fold selectivity over B-Raf, GCN2 and a panel of 387 other kinases. Synonyms: 4-[2-Amino-4-methyl-3-(2-methyl-6-quinolinyl)benzoyl]-1,2-dihydro-1-methyl-2,5-diphenyl-3H-pyrazol-3-one hydrochloride. Grade: ≥98%. CAS No. 1883548-84-2. Molecular formula: C34H28N4O2·HCl. Mole weight: 561.07. | |
| AWL-II-38.3 | AWL-II-38.3 is a potent ephrin-A receptor (EphA3) kinase inhibitor. AWL-II-38.3 does not exhibit significant cellular activity against Src-family kinases nor against b-raf[1][2][1][2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1135205-94-5. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-18832. | |
| AZ 628 | AZ 628 is a pan-Raf kinase inhibitor with IC 50 s of 105, 34 and 29 nM for B-Raf , B-RafV600E , and c-Raf-1 , respectively. Uses: Scientific research. Group: Signaling pathways. CAS No. 878739-06-1. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-11004. | |
| AZ 628 | AZ628 is a potent, ATP-competitive inhibitor of Raf kinases (IC50 values are 29, 34 and 105 nM for c-Raf1, B-RafV600E and wild-type B-Raf, respectively). It displays selectivity for Raf kinases over a panel of 150 other kinases and inhibits activation of tyrosine protein kinases such as VEGFR2, Lyn, Flt1 and Fms. Synonyms: AZ628; AZ-628; AZ 628. Grade: >98%. CAS No. 878739-06-1. Molecular formula: C27H25N5O2. Mole weight: 451.52. | |
| Belvarafenib | Belvarafenib (HM95573) is a potent and pan RAF (Rapidly Accelerated Fibrosarcoma) inhibitor, with IC 50 s of 56 nM, 7 nM and 5 nM for B-RAF, B-RAF v600E and C-RAF respectively [1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: HM95573; GDC-5573; RG6185. CAS No. 1446113-23-0. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-109080. | |
| BGB-283 | BGB-283 is a selective Epidermal growth factor receptor and Proto oncogene protein b raf inhibitor under the development of BeiGene. BGB-283 shows antitumor activity in B-RAF Mutated Colorectal Cancers. In vitro, BGB-283 can inhibit B-RAFV600E-activated ERK phosphorylation and cell proliferation. In vivo, BGB-283 can lead to dose-dependent tumor growth inhibition accompanied by partial and complete tumor regressions in both cell-line derived and primary human colorectal tumor xenografts bearing B-RAFV600E mutation. Phase I clinical trials for the treatment of solid tumours are on-going. Uses: Solid tumours. Synonyms: UNII-8762XZS5ZF; 8762XZS5ZF; BGB-283; BGB 283; BGB283; Beigene-283; Beigene283; Beigene 283; Lifirafenib; Compound 2.2b; Beigene-283; GTPL8958; 5-[[(1R,1aS,6bR)-1-[6-(trifluoromethyl)-1H-benzimidazol-2-yl]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-5-yl]oxy]-3,4-dihydro-1H-1,8-naphthyridin-2-one. Grade: 98%. CAS No. 1446090-77-2. Molecular formula: C25H17F3N4O3. Mole weight: 478.31. | |
| B-Raf IN 1 | B-Raf IN 1 is a highlt potent and selective B-Raf inhibitor. It was equipotent against c-Raf. Synonyms: B-Raf-IN-1; B-Raf-IN 1; B-Raf-IN1; MDK36057; MDK-36057; MDK 36057. Grade: >98%. CAS No. 950736-05-7. Molecular formula: C29H24F3N5O. Mole weight: 515.53. | |
| B-Raf IN 2 | B-Raf IN 2 is a potent and selective BRAF inhibitor extracted from patent WO2021116055A1, compound Ia. CAS No. 2649372-20-1. Molecular formula: C20H17F2N5O4S. Mole weight: 461.44. | |
| BRAF inhibitor | BRAF inhibitor is a B-Raf inhibitor with anti-tumor activity extracted from patent WO/2011103196 A1, Compound P-0850. Uses: Scientific research. Group: Signaling pathways. CAS No. 918505-61-0. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg. Product ID: HY-10247. | |
| CEP-32496 hydrochloride | CEP-32496, also known as AC013773, is an orally available v-raf murine sarcoma viral oncogene homolog B1 (B-raf) serine/threonine protein kinase inhibitor with potential antineoplastic activity. CEP-32496 specifically and selectively inhibits the activity of the mutated form (V600E) of B-raf kinase. This inhibits the activation of the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway and may result in a decrease in the proliferation of tumor cells expressing the mutated B-raf gene. The Raf mutation BRAF V600E, in which valine is substituted for glutamic acid at residue 600, is frequently found in a variety of human tumors and results in the constitutive activation of the RAF/MEK/ERK signaling pathway that regulates cellular proliferation and survival. Synonyms: CEP-32496; CEP32496; CEP 32496; AC013773; AC 013773; AC-013773. CAS No. 1227678-26-3. Molecular formula: C24H23ClF3N5O5. Mole weight: 553.92. | |
| Dabrafenib | Dabrafenib (GSK2118436A) is an ATP-competitive inhibitor of Raf with IC 50 s of 5 nM and 0.6 nM for C-Raf and B-Raf V600E , respectively [4]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: GSK2118436A; GSK2118436. CAS No. 1195765-45-7. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg; 200 mg; 500 mg; 1 g. Product ID: HY-14660. | |
| Dabrafenib | Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.8 nM, with 4- and 6-fold less potency against B-Raf(wt) and c-Raf, respectively. Uses: Antineoplastic agents. Synonyms: N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluoro-benzenesulfonamide; Dabarefenib; GSK 2118436; Tafinlar. Grade: >98%. CAS No. 1195765-45-7. Molecular formula: C23H20F3N5O2S2. Mole weight: 519.56. | |
| Dabrafenib Mesylate | Dabrafenib, also known as GSK2118436, is an orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations. On May 29, 2013, FDA approved this drug. Synonyms: N-(3-(5-(2-aminopyrimidin-4-yl)-2-(tert-butyl)thiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide methanesulfonate; Dabrafenib mesylate; GSK 2118436B; GSK2118436B; GSK-2118436B; GSK2118436 Methane sulfonate salt; Brand name: Taflinar. Grade: >98%. CAS No. 1195768-06-9. Molecular formula: C24H24F3N5O5S3. Mole weight: 615.67. | |
| Des-(4-chloro-3-trifluoromethyl)-4-(methyl-4-hydroxypicolinate) Sorafenib | Des-(4-chloro-3-trifluoromethyl)-4-(methyl-4-hydroxypicolinate) Sorafenib is one of Sorafenib impurities. Sorafenib is a polykinase inhibitor of Raf-1, B-Raf and VEGFR-2 and is an anti-tumor drug. Synonyms: 4-[4-[[[[4-[[2-[(Methylamino)carbonyl]-4-pyridinyl]oxy]phenyl]amino]carbonyl]amino]phenoxy]-methyl ester-2-pyridinecarboxylic Acid; Sorafenib Impurity C; Sorafenib Impurity 6. Grade: > 98%. CAS No. 2204442-52-2. Molecular formula: C27H23N5O6. Mole weight: 513.50. | |
| Doramapimod | Doramapimod (BIRB 796) is an orally active, highly potent p38 MAPK inhibitor, which has an IC50 for p38?=38 nM, for p38?=65 nM, for p38?=200 nM, and for p38?=520 nM. Doramapimod has picomolar affinity for p38 kinase (Kd=0.1 nM). Doramapimod also inhibits B-Raf with an IC50 of 83 nM[1][2]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: BIRB 796. CAS No. 285983-48-4. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg; 200 mg; 500 mg. Product ID: HY-10320. | |
| EBI-907 | EBI-907, an isoquinolin derivative, has been found to be a B-RafV600E inhibitor and exhibit activities against some oncogenic kinases at some extent. The researches of it against breast cancer is still in progress. Synonyms: EBI-907; EBI 907; EBI907; N-(2-chloro-3-(1-cyclopropyl-8-methoxy-3H-pyrazolo[3,4-c]isoquinolin-7-yl)-4-fluorophenyl)-3-fluoropropane-1-sulfonamide. Grade: 98%. CAS No. 1581764-31-9. Molecular formula: C23H21ClF2N4O3S. Mole weight: 506.95. | |
| GDC-0879 | GDC-0879 is a potent and selective B-Raf inhibitor with an IC50 of 0.13 nM. Uses: Scientific research. Group: Signaling pathways. CAS No. 905281-76-7. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-50864. | |
| GSK-114 | GSK-114 is a selective TNNI3 Interacting Kinase (TNNI3K) inhibitor with IC50 of 25nM. GSK-114 shows significant bias for TNNI3K over B-Raf, exceptional broad spectrum kinase selectivity and adequate oral exposure to enable its use in cellular and in vivo studies. Ralated studies has shown that TNNI3 Interacting Kinase has been linked to the progression of dilated cardiomyopathy, cardiac hypertrophy, and ischemia/reperfusion injury using models that employ TNNI3K overexpressing or TNNI3K knockout animals. Synonyms: GSK-114; GSK 114; GSK114; 3-((6,7-dimethoxyquinazolin-4-yl)amino)-4-(dimethylamino)-N-methylbenzenesulfonamide; 1301760-19-9 (2HCl). Grade: 98%. CAS No. 1301761-96-5. Molecular formula: C19H23N5O4S. Mole weight: 417.48. | |
| GSK-114 2Hcl | GSK-114 is a potent and selective TNNI3K inhibitor (TNNI3 IC50 = 25nM; B-RafV600E IC50 = 1000 nM). GSK-114 displays significant bias (40-fold) for TNNI3K over B-Raf, exceptional broad spectrum kinase selectivity, and adequate oral exposure to enable its use in cellular and in vivo studies. Synonyms: GSK-114 2Hcl; GSK114 2Hcl; GSK 114 2Hcl. CAS No. 1301760-19-9. Molecular formula: C19H23N5O4S.2HCl. Mole weight: 495.484. | |
| HG6-64-1 | HG6-64-1 is a potent and selective B-Raf and mutant B-Raf inhibitor; more information can be found in Patent WO 2011090738. Synonyms: HG-6-64-1; HG 6 64 1; HG6641. Grade: >98%. CAS No. 1315329-43-1. Molecular formula: C32H34F3N5O2. Mole weight: 577.64. | |
| KG5 | KG5 is an orally active dual PDGFRβ and B-Raf allosteric inhibitor. KG5 also inhibits Flt3 , KIT and c-Raf. KG5 has anticancer, antiangiogenic activities [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 877874-85-6. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-15198. | |
| KG-5 | KG-5 is an orally available PDGFRß and B-Raf allosteric inhibitor. Uses: Designed for use in research and industrial production. Additional or Alternative Names: KG-5; KG 5; KG5. Product Category: Inhibitors. Appearance: Solid powder. CAS No. 877874-85-6. Molecular formula: C20H16F3N7OS. Mole weight: 459.45. Purity: >98%. IUPACName: 2-(Methylthio)-6-[4-[5-[[3-(trifluoromethyl)phenyl]amino]-1H-1,2,4-triazol-3-yl]phenoxy]-4-pyrimidinamine. Canonical SMILES: NC1=NC(SC)=NC(OC2=CC=C(C3=NNC(NC4=CC=CC(C(F)(F)F)=C4)=N3)C=C2)=C1. Product ID: ACM877874856. Alfa Chemistry ISO 9001:2015 Certified. Categories: KG 51. |  |
| LUT014 | LUT014 is a B-Raf inhibitor with an IC 50 of 11.7 nM, and developed to reduce dose-limiting acneiform lesions associated EGFR Inhibitors treatment. Extracted from patent WO 2019026065A2 [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 2274819-46-2. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-111940. | |
| Mavorixafor free base | Mavorixafor, also known as AMD11070, AMD070, X4P-001, is an orally bioavailable and potent CXCR4 inhibitor. AMD11070 is an antagonist of SDF-1α ligand binding (IC50 = 12.5 ± 1.3 nM), inhibits SDF-1 mediated calcium flux (IC50 = 9.0 ± 2.0 nM) and SDF-1α mediated activation of the CXCR4 receptor as measured by a Eu-GTP binding assay (IC50 =39.8 ± 2.5 nM) or a [(35)S]-GTPγS binding assay (IC50 =19.0 ± 4.1 nM), and inhibits SDF-1α stimulated chemotaxis (IC50 =19.0 ± 4.0 nM). AMD11070 abrogates melanoma cell migration and is significantly more effective than AMD3100. AMD11070 represents a novel therapeutic strategy for both B-RAF wild-type and mutated melanomas. Uses: Designed for use in research and industrial production. Additional or Alternative Names: AMD11070, AMD 11070, AMD-11070, AMD070, AMD 070, AMD-070, X4P-001, X49001, X4P 001, Mavorixafor. Product Category: Antagonists. Appearance: Solid powder. CAS No. 558447-26-0. Molecular formula: C21H27N5. Mole weight: 349.48. Purity: >95%. IUPACName: (S)-N1-((1H-benzo[d]imidazol-2-yl)methyl)-N1-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine. Canonical SMILES: NCCCCN([C@@H]1C2=NC=CC=C2CCC1)CC3=NC4=C(N3)C=CC=C4. Product ID: ACM558447260. Alfa Chemistry ISO 9001:2015 Certified. | |
| Mosperafenib | BRAF inhibitor. RG6344 can be used for the study of BRAF V600-mutant solid tumors, such as colorectal cancer (CRC)[1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: RG6344; RO7276389; B-Raf IN 2. CAS No. 2649372-20-1. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-145120. | |
| PDGFRb/RAF Kinase Inhibitor | An orally bioavailable amino-triazole compound that is shown to bind to the inactive conformations of both PDGFRb and Raf kinases (allosteric, Type II inh), and acts as a potent inhibitor of Flt3, Kit, PDGFRa and PDGFRb (=52, 170, 300 and 520nM, respectively) with selectivity over B-Raf, p38a, FGFR2 and VEGFR2 (>10uM) in a multi-kinase panel. Completely blocks the phosphorylations of MEK-1/2 S217/S221, ERK-1/2 T202/Y204 in FGF-stimulated HUVECs, PDGFRb in PDGF-BB-stimulated VSMCs, ERK-1/2 T202/Y204 in 1205Lu-B Raf V600E cells, and C-Raf S338 at 10uM. Reduces FGF-induced angiogenesis in mouse Matrigel model (50mg/kg, i.p., bid) and selectively induces apoptosis in the endothelium; further, suppresses orthotopic renal cell carcinoma growth in mice (100mg/kg, p.o., qd). Group: Biochemicals. Alternative Names: 6- (4- (5- (3- (Trifluoromethyl) phenylamino) -4 H-1,2,4-triazol-3-yl)phenoxy)-2-(methylthio)pyrimidin-4-amine, PDGFR Tyrosine Kinase Inhibitor XXII. Grades: Highly Purified. Pack Sizes: 10mg. Molecular Formula: C??H??F?N?OS, Molecular Weight: 459.6. US Biological Life Sciences. | Worldwide |
| PLX4720 | Potent and selective cell permeable B-Raf (V600E) and c-Raf-1 (Y340D/Y341D) inhibitor. Antitumor compound. ERK phosphorylation is potently inhibited exclusive in B-Raf(V600E)-bearing tumor cell lines. Group: Biochemicals. Alternative Names: N-(3-(5-Chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl)propane-1-sulfonamide, Raf Kinase Inhibitor V. Grades: Highly Purified. CAS No. 918505-84-7. Pack Sizes: 5mg, 25mg. Molecular Formula: C??H??ClF?N?O?S. US Biological Life Sciences. | Worldwide |
| PLX-4720 | PLX-4720 is a potent and selective inhibitor of B-RafV600E with IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), and 10-fold selectivity for B-RafV600E than wild-type B-Raf. Uses: Scientific research. Group: Signaling pathways. CAS No. 918505-84-7. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg. Product ID: HY-51424. | |
| Raf inhibitor 1 | Raf inhibitor 1 is a potent Raf kinase inhibitor with Kis of 1 nM, 1 nM, and 0.3 nM for B-RafWT, B-RafV600E, and C-Raf, respectively. Uses: Scientific research. Group: Signaling pathways. CAS No. 1093100-40-3. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-14177. | |
| SB-590885 | SB-590885 is a potent B-Raf inhibitor with a K i of 0.16 nM, and has 11-fold greater selectivity for B-Raf over c-Raf, without inhibition to other human kinases. Uses: Scientific research. Group: Signaling pathways. CAS No. 405554-55-4. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-10966. | |
| Sorafenib | Sorafenib (Bay 43-9006) is a potent and orally active Raf inhibitor with IC 50 s of 6 nM and 20 nM for Raf-1 and B-Raf , respectively. Sorafenib is a multikinase inhibitor with IC 50 s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2 , VEGFR3 , PDGFRβ , FLT3 and c-Kit , respectively. Sorafenib induces autophagy and apoptosis. Sorafenib has anti-tumor activity. Sorafenib is a ferroptosis activator [1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: Bay 43-9006. CAS No. 284461-73-0. Pack Sizes: 10 mM * 1 mL; 100 mg; 1 g. Product ID: HY-10201. | |
| Sorafenib | Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM, respectively. Synonyms: BAY 43-9006. Grade: >98%. CAS No. 284461-73-0. Molecular formula: C21H16ClF3N4O3. Mole weight: 464.82. | |
| Sorafenib tosylate | Sorafenib Tosylate (Bay 43-9006) is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM, respectively. Synonyms: Sorafenib p-toluenesulfonate; BAY 43-9006 Mono-p-tosylate; BAY 54-9085; Nexavar(R); 1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-((2-(methylcarbamoyl)pyridin-4-yl)oxy)phenyl)urea mono(4-methylbenzenesulfonate); 2-Pyridinecarboxamide, 4-(4-((((4-chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-, mono(4-methylbenzenesulfonate); Bay 43-9006. Grade: ≥ 95%. CAS No. 475207-59-1. Molecular formula: C28H24ClF3N4O6S. Mole weight: 637.03. | |
| Sorafenib tosylate | Sorafenib tosylate (Bay 43-9006 tosylate) is a potent and orally active Raf inhibitor with IC 50 s of 6 nM and 20 nM for Raf-1 and B-Raf , respectively. Sorafenib tosylate is a multikinase inhibitor with IC 50 s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2 , VEGFR3 , PDGFRβ , FLT3 and c-Kit , respectively. Sorafenib tosylate induces autophagy and apoptosis. Sorafenib tosylate has anti-tumor activity. Sorafenib tosylate is a ferroptosis activator [1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: Bay 43-9006 tosylate. CAS No. 475207-59-1. Pack Sizes: 10 mM * 1 mL; 100 mg; 500 mg. Product ID: HY-10201A. | |
| Uplarafenib | Uplarafenib (B-Raf IN 10) (Compound C09) is a BRAF inhibitor with an IC 50 between 50 and 100 nM. Uplarafenib shows antitumor activity [1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: B-Raf IN 10. CAS No. 1425485-87-5. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-148059. | |
| Vemurafenib | Vemurafenib (PLX4032) is a first-in-class, selective, potent inhibitor of B-RAF kinase, with IC 50 s of 31 and 48 nM for RAF V600E and c-RAF-1, respectively [1] [4]. Vemurafenib induces cell autophagy [5]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: PLX4032; RG7204; RO5185426. CAS No. 918504-65-1. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 500 mg. Product ID: HY-12057. | |
| Vemurafenib-[d7] | Vemurafenib-[d7] is the labelled analogue of Vemurafenib, which is a B-Raf enzyme inhibitor used for the treatment of late-stage melanoma. Synonyms: Vemurafenib D7. CAS No. 1365986-73-7. Molecular formula: C23H11D7ClF2N3O3S. Mole weight: 496.97. | |
| ZM 336372 | Cell-permeable. A potent, selective and ATP-competitive inhibitor of c-Raf in vitro (IC50 = 70nM for inhibition of human c-Raf). Displays 10-fold selectivity over B-Raf. Also inhibits SAPK2/p38 (IC50= 2uM). Group: Biochemicals. Alternative Names: 3- (Dimethylamino) -N- [3- [ (4-hydroxybenzoyl) -amino] -4-methylphenyl] benzamide. Grades: Highly Purified. CAS No. 208260-29-1. Pack Sizes: 1mg. US Biological Life Sciences. | Worldwide |
Our database is helping our users find suppliers everyday.
